Dr. Inman on Biomarkers for Immunotherapy in Bladder Cancer

Brant Inman, MD
Published Online: Thursday, Nov 09, 2017



Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

There are not currently good biomarkers for immunotherapy, explains Inman. However, the molecular subtypes of bladder cancer can predict response to immunotherapy.

According to Inman, these biomarkers are more telling about the biology of the tumor, rather than the response to a specific treatment.
 


Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

There are not currently good biomarkers for immunotherapy, explains Inman. However, the molecular subtypes of bladder cancer can predict response to immunotherapy.

According to Inman, these biomarkers are more telling about the biology of the tumor, rather than the response to a specific treatment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x